NASDAQ$VRCA
Verrica Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Verrica reported second quarter 2024 financial results with YCANTH revenue of $4.9M and announced positive preliminary topline results of Phase 2 clinical study of VP-315.
Verrica Pharmaceuticals reported a net product revenue of $4.9 million in the second quarter of 2024, driven by YCANTH sales. The company is progressing with its clinical pipeline, including positive Phase 2 results for VP-315 and preparations for a Phase 3 trial for common warts. Net loss for the quarter was $17.2 million, or $0.37 per share.
- Recognized net product revenue of $4.9 million in Q2 2024 from YCANTH.
- Announced positive preliminary results from Phase 2 study of VP-315 for basal cell carcinoma.
- Progressing towards global Phase 3 trial for YCANTH in common warts, expected to begin in 1H 2025.
- Added Cencora, Inc. as a specialty distributor in Q2 2024 to grow YCANTH distribution.
Headline financials
Revenue & EPS history
Verrica · Revenue · Quarterly
$5.18M
Forward guidance
Verrica anticipates continued growth in YCANTH prescriptions throughout the latter half of 2024, driven by the receipt of a permanent J-Code, progress in removing unapproved cantharidin products from the market, growing insurance coverage, and expanded distribution capabilities.
Tailwinds
- Expect YCANTH prescription growth to continue quarter over quarter in the second half of 2024.
- Permanent J-Code for YCANTH went into effect on April 1, streamlining product coverage and reimbursement.
- Made progress in removing unapproved, compounded cantharidin distributed by Dormer Laboratories.
- Growing insurance coverage for YCANTH.
- Expansion of distribution capabilities.
Headwinds
- Uncertainties inherent in the drug development process and the regulatory approval process.
- Reliance on third parties over which Verrica may not always have full control.
- Risks and uncertainties described in Verrica's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
- Potential for actual results to differ materially from forward-looking statements.
- Verrica's ability to fund its operations into the first quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-1.1%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+18.6%
Q1 2024
Best reaction
-47.9%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -15.3% | -19.9% | |
| Q4 2025 | +4.7% | +3.2% | -14.5% | |
| Q3 2025 | +3.2% | +15.8% | +104.7% | |
| Q1 2025 | +2.9% | -0.8% | -3.0% | |
| Q4 2024 | -7.6% | +0.5% | -25.3% | |
| Q3 2024 | -47.9% | -45.8% | -22.2% | |
| Q2 2024 | -44.8% | -43.8% | -62.6% | |
| Q1 2024 | +18.6% | +8.4% | +7.3% | |
| Q4 2023 | -3.0% | -10.1% | +3.5% | |
| Q3 2023 | -13.6% | -17.7% | +7.6% | |
| Q2 2023 | +7.6% | +1.6% | -18.5% | |
| Q1 2023 | -1.4% | -7.1% | -13.9% | |
| Q4 2022 | -6.9% | +1.5% | -21.6% | |
| Q3 2022 | -3.1% | +3.1% | +43.7% | |
| Q2 2022 | +17.1% | +9.6% | +18.8% | |
| Q1 2022 | -1.6% | -7.8% | -63.0% | |
| Q4 2021 | +1.3% | -7.7% | +1.9% | |
| Q3 2021 | -4.2% | -5.9% | -22.2% | |
| Q2 2021 | -1.6% | -0.7% | +12.6% | |
| Q1 2021 | -0.8% | -0.2% | -14.8% | |
| Q4 2020 | -9.6% | -0.2% | +1.3% | |
| Q3 2020 | +13.9% | +13.1% | +32.3% | |
| Q2 2020 | +5.6% | +4.8% | +29.6% | |
| Q1 2020 | +10.5% | +2.8% | +24.0% | |
| Q4 2019 | -12.1% | -7.5% | +31.3% | |
| Q3 2019 | +0.8% | +4.0% | -7.3% | |
| Q2 2019 | +2.6% | -9.3% | -2.3% | |
| Q1 2019 | +1.0% | -3.3% | -23.4% | |
| Q4 2018 | -7.5% | +1.1% | -8.0% | |
| Q3 2018 | -3.8% | +5.6% | -22.7% | |
| Q2 2018 | -0.9% | +2.7% | +13.8% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro